Article info

Download PDFPDF
Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer

Authors

  1. Correspondence to Carmen Maria Valencia Soto, Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, 39008 Santander, Cantabria, Spain; carmenmaria.valencia{at}scsalud.es
View Full Text

Citation

Valencia Soto CM, Villacañas Palomares MV, Garcia-Avello Fernández-Cueto A, et al
Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer

Publication history

  • Received August 26, 2021
  • Accepted March 24, 2022
  • First published April 5, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.